Cytometric Therapeutics is advancing a new era of precision oncology by combining live-cell functional testing with translational research. Our mission is to develop therapies that target disease while respecting the individuality of each patient’s biology. We believe precision medicine should unite scientific accuracy with compassion and measurable results.
Doctors Larry Weisenthal and William Grace have collaborated for 38 years on testing anti-cancer drugs in the tissue cultures of actual cancer patients.
In pursuit of effective therapies, they discovered a new therapy with the goal of treatment to increase dramatically the effectiveness of standard chemotherapeutic agents.
The therapy has been tested on over a dozen types of cancer, and Cytometric Therapeutics is preparing for clinical trials this year.
WCG Precision Therapy, a wholly owned subsidiary of Cytometric Therapeutics, works with physicians to identify effective drug combinations for an individual patient’s cancer. Using functional tumor response testing, WCG evaluates how a patient’s living tumor cells respond to available therapies and drug combinations. These findings help physicians select treatment strategies tailored to the biology of each patient’s tumor. Cytometric Therapeutics builds on this clinical insight by developing new therapeutic agents and treatment strategies informed by the response patterns observed through WCG Precision Therapy.
